Special Use Permit For Ivermectin “Issued Per Patient” — Domingo

A special use permit for ivermectin was “issued per patient”, according to Domingo.

Food and Drug Administration (FDA) Director-General Eric Domingo on Saturday said that a special use permit for human grade Ivermectin was “issued per patient”.

Domingo Ivermectin

In a report on GMA News Online, Domingo said that the compassionate special permit for the use of human grade Ivermectin as COVID-19 treatment was “issued per patient”.

Domingo explained in an interview on “Dobol B TV” that an application was needed before the FDA can issue the compassionate special permit to a hospital.

Lahat po ‘yan bawat ospital kumukuha ng compassionate special permit kasi kontrolado po sa CSP kung ilang tableta, kung kaninong pasyente nila gagamitin, kung saan manggagaling na bansa, ano ang registration sa bansa na ‘yon. Particular po ang compassionate special permit for each patient, for each hospital, and doctor,” Domingo said in an interview.

READ ALSO | Domingo: Ivermectin Still Not For Distribution Despite FDA’s Compassionate Use Approval

Domingo’s remark came after questions on the Food and Drug Administration’s approval of the compassionate special permit to an undisclosed hospital were raised.

Moreover, Domingo said that medicines that were currently approved for COVID-19 treatment — including Remdisivir — were also used under compassionate special permits.

The application for compassionate use permits, according to Domingo, can be filed before the Food and Drug Administration and can be acted upon within 24 hours.

Domingo then reiterated that the “compassionate use permit” was different from the “certificate of product registration”.

Prior to this, Domingo said that human grade Ivermectin was still not for distribution despite the FDA approval of an undisclosed hospital’s application for a compassionate use permit.

For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.

Leave a Comment